DaVita (NYSE: DVA) reported first-quarter 2025 results that came in slightly ahead of Wall Street estimates, supported by steady treatment volumes and disciplined cost management. However, shares dipped in pre-market trading following the announcement.
The kidney care services provider posted adjusted earnings of $2.00 per share, surpassing the consensus estimate of $1.96. Revenue rose 5.1% year-over-year to $3.22 billion, just above the $3.2 billion analyst forecast.
Operating income for the quarter totaled $439 million, with an operating margin of 13.6%. U.S. dialysis treatment volumes remained largely flat compared to the previous quarter, averaging 91,793 treatments daily.
DaVita continued to return capital to shareholders, repurchasing 3.7 million shares during the quarter at an average price of $148.94 per share, totaling $550 million. An additional 1.7 million shares were bought back for $259 million through May 12.
The company maintained its full-year 2025 outlook, forecasting adjusted operating income between $2.01 billion and $2.16 billion, adjusted diluted EPS in the range of $10.20 to $11.30, and free cash flow of $1 billion to $1.25 billion.
Earlier this year, Berkshire Hathaway (NYSE: BRK.B) trimmed its position in DaVita, selling 750,000 shares between February 14 and 19. The sales, valued at about $115 million, reduced Berkshire’s stake by roughly 2%.
Following the transactions, Berkshire holds 35.14 million shares of DaVita, worth approximately $5.4 billion. This represents an estimated 44% ownership, based on DaVita’s 80 million outstanding shares as of January 31.
As of the latest update, DaVita (NYSE: DVA) shares are down 0.30%, trading at $143.99.
David Kirakosyan is a seasoned financial journalist with nearly a decade of hands-on experience in covering the U.S. stock markets. Since 2016, he has written thousands of equity news articles, detailed market analyses, and investment insights for trusted platforms like Benzinga, Investing.com, and StreetInsider. David holds a Master of Science in Finance and is a Level 2 CFA® candidate, reflecting his deep commitment to financial expertise and ethical standards. His reporting combines real-world market experience with a strong academic foundation, helping readers make informed decisions backed by reliable information. Read Full Bio
